INS and metabolic dysfunction-associated steatotic liver disease: To compare the change of intrahepatic lipids (IHL) in type 2 diabetic patients with nonalcoholic fatty liver disease after a 26-week treatment of liraglutide, sitagliptin, or insulin glargine per day combined with metformin.